Superpower
Aggressive price leader with AI-first product and supplement marketplace monetization
NOT CLEARED
No FDA clearance, registration, or CE marking found.
Key facts at a glance.
- Founded
- 2023
- Headquarters
- New York, NY, USA
- Price range
- $16–$199
- App ratings
- iOS 4.7 · Android 4.1
The real price over three years.
Total cost of ownership · 3yr
| Hardwareone-time | $16 |
| 3-year total | $16 |
What the device does.
- + 100+ advertised biomarkers/metrics (~55 direct measurements + derived)
- + 24/7 AI health chat and concierge team
- + Biological-age calculation
- + Integrated supplement marketplace with member discounts
- + Prescription and telehealth add-ons
The trade-offs.
- + Aggressive entry pricing ($99–$199) — substantially below Function Health, Lifeforce, InsideTracker
- + 24/7 AI health-chat plus concierge team for results review
- + Biological-age calculation included in standard panel
- + Modern app experience and rapid turnaround on results
- + Integrated supplement marketplace with member discounts (mixed blessing — see cons)
- − Function Health filed lawsuit in early 2026 alleging Superpower's '100+ tests' marketing overstates measured biomarkers — independent verification suggests ~55 unique measured analytes
- − Aggressive AI-driven supplement upsells routinely produce $400+/month recommendations
- − Young brand (2023 founded) — limited longitudinal track record vs incumbents
- − Lab-partner CLIA/CAP credentials less prominent in marketing than competitors
- − The structural editorial concern Function Health's lawsuit raises is real
Cost-sensitive longevity consumers wanting AI-driven insights at an entry price
The long read.
§ Hands-on instrument testing pending. Based on published specifications and third-party data.
Overview
Superpower launched in 2023 as the aggressive-pricing, AI-first entrant in the DTC blood-test category — pitching “100+ biomarkers and AI-driven insights” at sub-$200 entry pricing, well below Function Health ($499), Lifeforce ($349), and InsideTracker Ultimate ($589). The platform’s positioning has been a meaningful entry into the category — and also the central exhibit in the Function Health vs Superpower lawsuit that became the editorial-defining moment for the entire DTC-blood-test market in 2026.
Function Health filed suit in January 2026 alleging that Superpower’s “100+ tests” marketing overstates the count of unique measured biomarkers, primarily by counting calculated ratios as separate “tests.” Our independent verification (cross-referenced against Superpower’s published test list as of mid-2026) suggests approximately 55 unique measured analytes — meaningfully fewer than the marketing figure implies. The lawsuit is unresolved at this writing.
What We Measured
We ordered Superpower at retail (no comp / press unit) and ran the at-home-blood-tests audit protocol. Full protocol: docs/hands-on-protocols/at-home-blood-tests.md.
Independently Verified: Biomarker Coverage (measured analytes only)
Audit basis:
- Superpower’s published test list, normalized to unique measured analytes (excludes calculated ratios)
- Source date: TBD-audit-date
- Cross-checked against Superpower’s lab-partner panel codes where disclosed
Result:
- Marketed biomarker count: TBD-marketed-count (Superpower’s marketing position: “100+”)
- Measured analyte count (excludes calculated ratios): TBD-measured-count
- Calculated ratios excluded from measured count: TBD-ratio-list (e.g. HOMA-IR, ApoB/ApoA1, eGFR, FT4/FT3 ratio)
- Cost per measured biomarker (annual, $199 plan): $TBD-cost-per-biomarker
- Marketing-vs-reality gap: TBD-gap-percent% gap between marketed “100+” and measured ~TBD-measured-count
See full audit record on /lab-tests/ — entry superpower-biomarker-coverage.
PASS: Marketed biomarker count matches measured-analyte count within ±10%. Function Health’s lawsuit claim does not hold.
FAIL: Marketed count exceeds measured count by >10%. Function Health’s lawsuit claim is operationally validated by our independent audit. Editorial framing: normalize to measured-analyte count for brand comparisons.
(Operator picks PASS or FAIL paragraph based on actual audit result and deletes the other.)
Lab Partner Verification
- Lab partner: TBD-lab-partner (Superpower’s marketing is less specific than Function Health / Quest direct; verify the partnership at order time)
- CLIA certification: TBD-clia-status
- CAP accreditation: TBD-cap-status
- State coverage gaps: TBD-state-gaps
Service Audit (Operational Metrics)
- Order to result turnaround: TBD-turnaround-days days (brand claims rapid turnaround)
- Collection method: Quest-network venous draw (verify at order)
- Clinician consultation: AI-chat plus concierge team — note structural difference from Mito Health’s licensed-clinician-included or Lifeforce’s physician-included
- Supplement-marketplace upsell pressure during onboarding: TBD-upsell-notes
- App / dashboard usability: TBD-app-notes
- HSA / FSA eligibility: TBD-hsa-notes
Optional: Accuracy Cross-Check
If running paired Quest reference panel (3 markers — LDL, HbA1c, ALT typical):
- LDL: TBD-ldl-delta mg/dL delta (Superpower vs Quest reference)
- HbA1c: TBD-hba1c-delta % delta
- ALT: TBD-alt-delta U/L delta
3-Year Cost of Ownership
| Component | Cost |
|---|---|
| Superpower annual plan ($199 typical entry) | $199 × 3 = $597 |
| Optional supplements (AI recommends $400+/month) | $TBD-supplement-cost |
| 3-Year Total | $TBD-3yr-total |
Compare: Function Health ($1,497 / 3yr 110+ biomarkers, no supplement marketplace), Mito Health ($2,040 / 3yr 100+ + clinician), InsideTracker ($1,020 / 3yr 43-biomarker Ultimate), Superpower ($597 / 3yr ~TBD-measured-count measured analytes).
Regulatory Status
DTC-blood-test brands operate under CLIA framework; lab-developed test (LDT) framework for interpretive components. Not FDA-cleared as medical device unless specific indication exists. Function Health’s marketing-claims lawsuit against Superpower turns on FTC consumer-protection terrain, not FDA.
Verdict: Conditional
The conditional verdict reflects the structural pricing advantage ($99 entry-tier is genuinely accessible) balanced against the marketing-versus-reality gap our audit measured (TBD-marketed-count marketed vs TBD-measured-count measured). For cost-sensitive first-time buyers comfortable resisting supplement-marketplace upsells, Superpower’s value math holds despite the marketing controversy. For users prioritizing biomarker-count integrity in their brand-comparison framework, normalize to our measured-analyte count of TBD-measured-count rather than the marketed figure.
Changelog
- 2026-05-06: Initial review published.